{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T01:58:14Z","timestamp":1775267894523,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.ejca.2010.06.014","type":"journal-article","created":{"date-parts":[[2010,7,14]],"date-time":"2010-07-14T09:01:51Z","timestamp":1279098111000},"page":"2506-2512","source":"Crossref","is-referenced-by-count":21,"title":["Prognostic impact of CD31-positive microvessel density in follicular lymphoma patients treated with immunochemotherapy"],"prefix":"10.1016","volume":"46","author":[{"given":"Minna","family":"Taskinen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esa","family":"Jantunen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veli-Matti","family":"Kosma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petri","family":"Bono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marja-Liisa","family":"Karjalainen-Lindsberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sirpa","family":"Lepp\u00e4","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2010.06.014_bib1","doi-asserted-by":"crossref","first-page":"6358","DOI":"10.1200\/JCO.2005.26.856","article-title":"Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors","volume":"23","author":"de Jong","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.06.014_bib2","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2010.06.014_bib3","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1200\/JCO.2006.06.4766","article-title":"Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients","volume":"24","author":"Alvaro","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.06.014_bib4","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1182\/blood-2006-04-018218","article-title":"High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma","volume":"108","author":"Carreras","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2010.06.014_bib5","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1200\/JCO.2006.06.4642","article-title":"Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome","volume":"24","author":"Lee","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.06.014_bib6","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1182\/blood-2007-11-125823","article-title":"Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP","volume":"111","author":"Taskinen","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2010.06.014_bib7","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.1158\/1078-0432.CCR-07-0778","article-title":"A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide\u2013doxorubicin\u2013vincristine\u2013prednisone","volume":"13","author":"Taskinen","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2010.06.014_bib8","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3324\/haematol.13574","article-title":"Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols","volume":"94","author":"de Jong","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.ejca.2010.06.014_bib9","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/annonc\/mdn666","article-title":"Angiogenesis and antiangiogenic therapy in non-hodgkin\u2019s lymphoma","volume":"20","author":"Ruan","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2010.06.014_bib10","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2010.06.014_bib11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1365-2141.2006.06255.x","article-title":"Differential gene expression in non-malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP","volume":"135","author":"Harjunpaa","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2010.06.014_bib12","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1097\/00000478-200109000-00007","article-title":"CD31 expression in intratumoral macrophages: a potential diagnostic pitfall","volume":"25","author":"McKenney","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ejca.2010.06.014_bib13","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1136\/jcp.56.8.638-a","article-title":"Caution should be taken in using CD31 for distinguishing the vasculature of lymph nodes","volume":"56","author":"Hattori","year":"2003","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.ejca.2010.06.014_bib14","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1034\/j.1600-0463.2003.1110406.x","article-title":"Tumour-type-specific capillary endothelial cell stainability in malignant B-cell lymphomas using antibodies against CD31, CD34 and factor VIII","volume":"111","author":"Norrby","year":"2003","journal-title":"APMIS"},{"key":"10.1016\/j.ejca.2010.06.014_bib15","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.1182\/blood-2009-11-253260","article-title":"Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163+ macrophages within the immediate sprouting micro-environment","volume":"115","author":"Clear","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2010.06.014_bib16","first-page":"19","article-title":"Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation","volume":"1796","author":"Maltby","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ejca.2010.06.014_bib17","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/nrc2444","article-title":"The role of myeloid cells in the promotion of tumour angiogenesis","volume":"8","author":"Murdoch","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2010.06.014_bib18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/(SICI)1097-0215(20000115)85:2<171::AID-IJC4>3.0.CO;2-W","article-title":"Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non-hodgkin\u2019s lymphomas","volume":"85","author":"Ribatti","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2010.06.014_bib19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/labinvest.3700697","article-title":"Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy","volume":"88","author":"Gratzinger","year":"2008","journal-title":"Lab Invest"},{"key":"10.1016\/j.ejca.2010.06.014_bib20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2141.2009.07942.x","article-title":"Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP)","volume":"148","author":"Gratzinger","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2010.06.014_bib21","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1080\/10428190601083241","article-title":"Angiogenesis in non-hodgkin\u2019s lymphoma: clinico-pathological correlations and prognostic significance in specific subtypes","volume":"48","author":"Jorgensen","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ejca.2010.06.014_bib22","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/1078-0432.154.11.1","article-title":"Increased vascularization predicts favorable outcome in follicular lymphoma","volume":"11","author":"Koster","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2010.06.014_bib23","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1080\/10428190902856808","article-title":"A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-hodgkin lymphoma: Southwest oncology group study S0108","volume":"50","author":"Stopeck","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ejca.2010.06.014_bib24","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1200\/JCO.2005.03.4801","article-title":"Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy","volume":"24","author":"Levine","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2010.06.014_bib25","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1182\/blood-2008-05-160747","article-title":"Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2","volume":"113","author":"Schliemann","year":"2009","journal-title":"Blood"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804910005125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804910005125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T02:40:37Z","timestamp":1685673637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804910005125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":25,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0959804910005125"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2010.06.014","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}